Article Text

Download PDFPDF
Photoreceptor status after antivascular endothelial growth factor therapy in exudative age-related macular degeneration
  1. K Sayanagi,
  2. S Sharma,
  3. P K Kaiser
  1. Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Dr P K Kaiser, Digital OCT Reading Center, Cole Eye Institute, 9500 Euclid Avenue, Desk i3, Cleveland, OH 44195, USA; pkkaiser{at}


Aims: To evaluate the photoreceptor layer status after antivascular endothelial growth factor (VEGF) therapy in choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT).

Design: Prospective, consecutive case series.

Methods: Twenty-three eyes of 22 patients with CNV secondary to AMD with foveal thickness less than 250 µm after treatment with anti-VEGF therapy and no obvious leakage on time domain OCT, and eight healthy subjects as controls, were imaged with at least one of four different SD-OCT devices. The inner and outer segment (IS/OS) photoreceptor layers were graded, and correlated with various characteristics including visual acuity.

Results: The IS/OS layer was detected in eight eyes (35%) of patients with AMD and all eyes (100%) of the healthy control subjects (p = 0.002). Eyes in patients with AMD with preserved IS/OS had a significantly better BCVA and mean change in BCVA, and were more likely not to have had previous laser treatment compared with eyes with absent IS/OS.

Conclusions: SD-OCT is a useful tool to visualise IS/OS status. IS/OS is often absent in patients who have received treatment with anti-VEGF therapy for CNV due to AMD. The IS/OS status after anti-VEFG therapy correlates with BCVA and mean change in vision.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests: KS has no proprietary interest in any aspect of this report. SS has received travel funding from Reichert, Inc. PK has received honoraria from Carl Zeiss Meditec, Heidelberg Engineering, Novartis, Genentech, and QLT, and research grant support from Genentech, Novartis, OSI-Eyetech and QLT.

  • Ethics approval: Ethics approval was provided by the Cleveland Clinic Institutional Review Board.

  • Patient consent: Obtained.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh